argenx SE announced it will acquire Forte Biosciences for approximately $2.2 billion in cash, paying $77 per share. This acquisition adds Forte's lead drug candidate FB102, a first-in-class anti-CD122 antibody with promising Phase 1b results in vitiligo and celiac disease, to argenx's immunology portfolio. The deal strengthens argenx's position in autoimmune disease treatment by expanding its pipeline with a novel approach targeting T-cell and NK-cell activity. The acquisition is expected to close in Q3 2026, subject to regulatory approvals and customary conditions.
Gregory Wong, the Chief Financial Officer of QuinStreet, has sold 11,704 shares of the company. This transaction may indicate a personal portfolio adjustment or a response to market conditions. Investors might watch for further insider trading activi...
Kahn Swick & Foti, LLC has started an investigation into Krispy Kreme following the company's pause in expanding its doughnut sales at McDonald's restaurants, which was a key part of its U.S. growth strategy. Despite earlier assurances of reaching 6,...
Kahn Swick & Foti, a law firm led by former Louisiana Attorney General Charles C. Foti, Jr., has launched an investigation into Geron Corporation. The probe focuses on whether Geron's executives misled investors about the growth prospects of its canc...
As Treasury bond yields have surged recently, especially in the past month, stocks with high dividend yields have become less attractive to investors. This is because higher "risk-free" yields make dividend-paying stocks comparatively less appealing....
Backpack's BP token briefly surged past $1.43 on September 25, marking a new all-time high and a 13% increase in 24 hours. Although the price later retreated to $1.29, the token maintained a strong gain of over 13% for the day. This price movement hi...
